Clinical parameters (median and IQR) in relation to a level of high sensitivity C reactive protein (hsCRP) in patients with the level of routine CRP <6 mg/litre
| hsCRP (mg/litre) | ||||||
|---|---|---|---|---|---|---|
| AS | Non-radiographic axial SpA | |||||
| Parameter | 0–1.9 (n=40) | 2.0–3.9 (n=14) | ≥4.0 (n=11) | 0–1.9 (n=46) | 2.0–3.9 (n=12) | ≥4.0 (n=3) |
| Fatigue, points NRS | 4.0 (2.0–7.8) | 4.5 (3.0–8.0) | 6.0 (2.0–7.0) | 5.0 (2.5–7.0) | 5.0 (3.0–7.0) | 7.0 (5.0–7.0) |
| General pain, points NRS | 4.0 (2.0–5.0) | 5.0* (3.8–6.3) | 5.0 (2.0–7.0) | 5.0 (2.0–7.0) | 4.5 (2.3–7.0) | 7.0 (5.0–8.0) |
| Spinal pain, points NRS | 3.5 (2.0–6.0) | 6.0* (3.8–7.3) | 5.0 (4.0–8.0) | 5.5 (2.0–7.0) | 5.5 (1.5–7.8) | 6.0 (6.0–8.0) |
| Night back pain, points NRS | 2.0 (1.0–5.0) | 4.5* (3.0–6.3) | 7.0* (3.0–7.0) | 4.5 (2.0–7.0) | 5.0 (0.8–7.8) | 8.0 (5.0–10.0) |
| Peripheral joint pain, points NRS | 1.0 (0–4.8) | 1.0 (0–5.0) | 1.0 (0–5.0) | 1.0 (0–4.3) | 4.0 (0–5.8) | 7.0 (3.0–7.0) |
| Local tenderness, points NRS | 1.0 (0–4.0) | 4.0 (1.5–5.0) | 3.0 (0–5.0) | 2.0 (0–4.5) | 3.0 (1.0–6.0) | 2.0 (2.0–2.0) |
| Morning stiffness, points NRS | 3.0 (1.0–5.8) | 5.5 (2.8–7.0) | 5.0 (2.0–8.0) | 4.0 (1.0–7.3) | 2.0 (1.0–6.0) | 6.0 (5.0–7.0) |
| BASDAI | 2.8 (1.4–5.5) | 3.9 (2.8–5.9) | 3.6 (1.7–5.7) | 3.6 (1.4–5.0) | 4.7 (2.0–5.3) | 3.6 (1.7–5.7) |
| BASFI | 1.3 (0.2–4.7) | 2.5 (1.4–3.7) | 3.0 (1.0–5.9) | 1.3 (0.3–3.7) | 2.7 (1.1–4.3) | 4.7 (4.0–5.4) |
| BASMI | 1.0 (1.0–2.8) | 1.0 (0–1.0) | 1.0 (1.0–3.0) | 1.0 (0–2.0) | 1.0 (1.0–2.0) | 2.0 (0–2.0) |
↵* p<0.05 in comparison to the first tertile (level of hsCRP 0–1.9 mg/litre).
AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; NRS, numerical rating scale; SpA, spondyloarthritis.